Company Registry

Lab11 Therapeutics LLC
Profile last edited on: 7/20/2022

Broad spectrum anti-viral drugs
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

223 Bedford Avenue
Brooklyn, NY 11211
   (917) 576-4742
Multiple Locations:   
Congressional District:   12
County:   Kings

Public Profile

Identified as working in the space of Broad Spectrum Anti-Virals, Lab11 Therapeutics LLC is identified as a startup biotech company using human genetics as a lead towards therapy development using the latest in technology to design, test, validate and improve drugs. Developing drugs that would allow to be prepared for novel viral pandemics, with a strong J&J association in New York and Washington DC, the firm is working on two programs developing host-mediated broad spectrum antivirals: 1) small-molecule broad spectrum, and 2) mRNA mediated delivery of host antiviral effectors, serving as broad spectrum antivirals. Broad spectrum antivirals do not exist.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2021 1 NIH $255,932
Transient Gene Therapy as Broad Spectrum Antiviral

Key People / Management

  Dusan Bogunovic -- CEO and President

SBIR firms in the news

There are no news available.